secwatch.observer — SEC 8-K summary
======================================

Issuer:     Jasper Therapeutics, Inc. (JSPR)
CIK:        0001788028
Form:       8-K
Filed at:   2023-01-27T23:59:59+00:00
Accession:  0001213900-23-005582
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Jasper Therapeutics closes $103.5M public offering of 69M shares at $1.50/share
-------------------------------------------------------------------------------

- Closed underwritten offering of 69,000,000 shares at $1.50, including 9M option shares.
- Gross proceeds of approximately $103.5M before underwriting discounts and expenses.
- Offering made under effective shelf registration statement (File No. 333-267777) filed Oct 2022.
- Lead book-running managers: Credit Suisse Securities and William Blair; Oppenheimer as passive book-runner.
- Company focuses on c-Kit antibody therapies for chronic spontaneous urticaria, MDS, and transplant conditioning.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1788028/000121390023005582/0001213900-23-005582-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1788028/000121390023005582/ea172298-8k_jasper.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-005582

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer